Opinion
Video
Actionable Insights for Health Care Decision Makers on Lp(a) Testing
Experts provide insights for health care decision makers on the importance of Lp(a) level assessment to help mitigate the risk of cardiovascular disease, including actionable steps for seamless integration.
This is a video synopsis/summary of an Insights involving Jaime Murillo, MD; Erin D. Michos, MD, MHS; and Michael D. Shapiro, DO.
Murillo emphasizes the need for dynamic guideline updates, real-world data utilization, and artificial intelligence integration in health care decision-making. He advocates for empowering individuals, especially in at-risk populations such as African American patients, through knowledge and collaboration with health care providers. Murillo underscores the importance of value-based care to incentivize preventive measures, citing lipoprotein(a) (Lp[a]) testing as a prime example for enhancing lifestyle and therapy strategies.
Michos discusses practical approaches for health care systems, utilizing electronic health records and targeting specific clinics for Lp(a) testing. She stresses the actionable nature of Lp(a) data even in the absence of specific lowering therapies, suggesting its measurement in all adults at least once. Michos emphasizes considering the whole person and their risk factors for informed risk management decisions.
Shapiro, DO, presents Lp(a) as a causal driver of atherosclerotic cardiovascular disease, advocating for universal screening. He highlights Lp(a)’s role in guiding personalized prevention and treatment strategies, including emerging Lp(a) lowering therapies. Shapiro urges health systems to implement universal Lp(a) testing now to enhance cardiovascular outcomes, especially in groups with disparities.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
